Back to Newsroom

International Stem Cell Corporation Completes Clinical Testing of a New Compound

CARLSBAD, CA–(Marketwired – August 06, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the Company completed clinical testing of a recently discovered compound, which the Company intends to utilize in skin care products marketed by Company’s wholly-owned subsidiary Lifeline Skin Care, Inc. (Lifeline). Topical treatment with the compound showed significant (p<0.01) improvement in skin elasticity and decrease in skin roughness in all subjects 4 and 8 weeks after the start of the study. In addition, the compound-treated group outperformed not only the baseline, but also the Retinol treated group. There were no adverse events reported in the compound-treated group, such as skin irritation, which has been reported as a common side effect of Retinol treatment.

Click here to read more